Paid Clinical Trials in Newark, DE

As of August 2026, 145 paid clinical trials are recruiting in Newark, Delaware. Compensation typically covers time, travel, and study visits, with stipends ranging from modest amounts for short outpatient studies to several thousand dollars for long or inpatient protocols.

Both patients with specific conditions and healthy volunteers can qualify. Most trials offer free study-related medical care alongside compensation.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: August 27, 2026.

Filter results

Filter results

State

City

Facility

Recruitment status

Phase

Study type

Intervention

Condition

Sex

Age

Healthy volunteers only

139 clinical trials

Get a weekly email when new trials open in Newark, DE.

Oxytocin Rest to Reduce Cesarean Delivery

for Prolonged Labor

1 location in Newark

Sponsor: Christiana Care Health Services

Sex: Female·Age: 18 - 55

Code: NCT06268431·Recruiting·Listed Feb 2024

Apply to this trial

Western Diet on Cardiometabolic and Immune Function

for Aging

1 location in Newark

Sponsor: University of Delaware

Sex: All·Age: 50 - 64·Accepts healthy volunteers

Code: NCT06528977·Recruiting·Listed Jul 2024

Apply to this trial

Online Motor Control in People With Parkinson's Disease

for Motor Control

1 location in Newark

Sponsor: University of Delaware

Sex: All·Age: 18 - 85·Accepts healthy volunteers

Code: NCT04616508·Recruiting·Listed Nov 2020

Apply to this trial

Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin

for Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8

Sites in Newark, Wilmington +61 more locations

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT07441681·Phase 3·Recruiting·Listed Mar 2026

Apply to this trial

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

for Gastric Cancer

Drug: Sonesitatug vedotin

Sites in Newark +71 more locations

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT07431281·Phase 3·Recruiting·Listed Feb 2026

Apply to this trial

Phase 3 Trial of VMX-C001 vs Usual Pharmacological Care in Patients Taking a FXa Direct Oral Anticoagulant Who Require Urgent Surgery With or Without Heparin.

for Blood Loss, Surgical

Sites in Newark +16 more locations

Sponsor: VarmX B.V.

Sex: All·Age: 18+

Code: NCT07288489·Phase 3·Recruiting·Listed Dec 2025

Apply to this trial

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

for Non-small Cell Lung Cancer (NSCLC)

Sites in Newark +47 more locations

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT07291037·Phase 3·Recruiting·Listed Dec 2025

Apply to this trial

A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

for Gastroesophageal Adenocarcinoma

Sites in Newark +5 more locations

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT07069712·Phase 2·Recruiting·Listed Jul 2025

Apply to this trial

A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event

for Cardiovascular Disease

Sites in Newark +309 more locations

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT07000357·Phase 3·Recruiting·Listed Jun 2025

Apply to this trial

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

for Graves' Disease

Drug: IMVT-1402

Sites in Newark +54 more locations

Sponsor: Immunovant Sciences GmbH

Sex: All·Age: 18 - 75

Code: NCT06727604·Phase 2·Recruiting·Listed Dec 2024

Apply to this trial

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

for Endometrial Carcinoma

Sites in Newark +330 more locations

Sponsor: National Cancer Institute (NCI)

Sex: Female·Age: 18+

Code: NCT05256225·Phase 3·Recruiting·Listed Feb 2022

Apply to this trial

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

for Untreated Follicular Lymphoma

Drug: Rituximab

Sites in Newark +56 more locations

Sponsor: AstraZeneca

Sex: All·Age: 18 - 130

Code: NCT06549595·Phase 3·Recruiting·Listed Aug 2024

Apply to this trial

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

for Non-squamous Non-small Cell Lung Cancer

Drug: Rilvegostomig

Sites in Newark +60 more locations

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT06627647·Phase 3·Recruiting·Listed Oct 2024

Apply to this trial

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

for Non-small Cell Lung Cancer

Drug: Rilvegostomig

Sites in Newark +64 more locations

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT06692738·Phase 3·Recruiting·Listed Nov 2024

Apply to this trial

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

for Carcinoma, Non-Small Cell Lung

Drug: Rilvegostomig

Sites in Newark +38 more locations

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT06868277·Phase 3·Recruiting·Listed Mar 2025

Apply to this trial

Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

for Hepatocellular Carcinoma

Drug: Rilvegostomig

Sites in Newark +30 more locations

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT06921785·Phase 3·Recruiting·Listed Apr 2025

Apply to this trial

Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS

for Acute Coronary Syndrome

Sites in Newark +147 more locations

Sponsor: DalCor Pharmaceuticals

Sex: All·Age: 45+

Code: NCT05918861·Phase 3·Recruiting·Listed Jun 2023

Apply to this trial

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

for HER2-positive Gastric Cancer

Drug: Rilvegostomig

Sites in Newark +44 more locations

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT06764875·Phase 3·Recruiting·Listed Jan 2025

Apply to this trial

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

for Head and Neck Squamous Cell Carcinoma

Drug: Petosemtamab

Sites in Newark +35 more locations

Sponsor: Merus B.V.

Sex: All·Age: 18+

Code: NCT06525220·Phase 3·Recruiting·Listed Jul 2024

Apply to this trial